Abiomed, Inc. (NASDAQ:ABMD) Director Martin P. Sutter sold 1,500 shares of the company’s stock in a transaction on Wednesday, November 18th. The stock was sold at an average price of $268.94, for a total transaction of $403,410.00. Following the sale, the director now directly owns 184,760 shares of the company’s stock, valued at approximately $49,689,354.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Abiomed stock opened at $268.21 on Friday. The firm has a market capitalization of $12.12 billion, a P/E ratio of 58.95, a P/E/G ratio of 3.18 and a beta of 1.42. The firm’s 50 day moving average is $272.01 and its two-hundred day moving average is $264.32. Abiomed, Inc. has a 52 week low of $119.01 and a 52 week high of $319.19.
Abiomed (NASDAQ:ABMD) last announced its earnings results on Tuesday, November 3rd. The medical equipment provider reported $1.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.87 by $0.49. The business had revenue of $209.80 million for the quarter, compared to analyst estimates of $202.89 million. Abiomed had a net margin of 25.89% and a return on equity of 15.34%. The company’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period last year, the firm posted $0.28 earnings per share. As a group, sell-side analysts predict that Abiomed, Inc. will post 4.08 earnings per share for the current year.
ABMD has been the subject of a number of analyst reports. SVB Leerink dropped their price objective on shares of Abiomed from $335.00 to $280.00 and set a “market perform” rating for the company in a report on Monday, October 12th. Morgan Stanley upped their price objective on shares of Abiomed from $152.00 to $217.00 and gave the company an “underweight” rating in a report on Friday, August 7th. Finally, BidaskClub lowered shares of Abiomed from a “buy” rating to a “hold” rating in a report on Tuesday, August 25th. Two analysts have rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company’s stock. Abiomed currently has a consensus rating of “Hold” and an average target price of $210.40.
Abiomed Company Profile
Abiomed, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.
Receive News & Ratings for Abiomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abiomed and related companies with MarketBeat.com's FREE daily email newsletter.